Atlas Trials

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Clinical trial NCT05637268 · UNKNOWN

Trial details

NCT number
NCT05637268
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Esophagus Cancer
Start date
2020-11-26
Primary completion
2024-06-01
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.